Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

J&J's CEO may be right. Customers of all kinds are demanding change.

In Medivation deal, Pfizer will gain an oncology blockbuster

In Medivation deal, Pfizer will gain an oncology blockbuster

Pfizer's commercial expertise in urology and oncology could help propel Medivation's Xtandi to new heights.

Five things for pharma marketers to know: Wednesday, April 6, 2016

Five things for pharma marketers to know: Wednesday, April 6, 2016

Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire

Five things for pharma marketers to know: Monday, January 11, 2016

Five things for pharma marketers to know: Monday, January 11, 2016

Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed

Accenture acquires Swiss pharma agency, adds digital marketing expertise

Accenture acquires Swiss pharma agency, adds digital marketing expertise

The consultancy purchased Boomerang Pharmaceutical Communications, its sixth acquisition in the past 12 months.

Five things for pharma marketers to know: Friday, December 4, 2015

Five things for pharma marketers to know: Friday, December 4, 2015

Pharma M&A expected to continue in 2016; Mylan receives government subpoena about marketing and pricing for doxycycline; KaloBios acquired rights to experimental drug to treat Chagas disease

Pfizer, Allergan to merge, creating pharma giant

Pfizer, Allergan to merge, creating pharma giant

The deal is estimated to bring in $2 billion in operational synergies, in addition to further commercializing Allergan's products outside the US.

Five things for pharma marketers to know: Monday, November 23, 2015

Five things for pharma marketers to know: Monday, November 23, 2015

Pfizer/Allergan merger creates world's largest drugmaker; Turing cuts Daraprim price for hospitals; CVS to cover Amgen's PCSK9 inhibitor

Five things for pharma marketers to know: Thursday, November 19, 2015

Five things for pharma marketers to know: Thursday, November 19, 2015

Pfizer reportedly nears deal with Allergan; health insurers are to blame for rising healthcare costs, according to report; a new fund seeks to invest in digital bio start-ups

Five things for pharma marketers to know: Monday, November 2, 2015

Five things for pharma marketers to know: Monday, November 2, 2015

Shire said it will acquire Dyax, which markets Kalbitor; Citron doesn't plan to release any additional allegations against Valeant; Myriad Genetics launches social-media campaign

Five things for pharma marketers to know: Thursday, October 29, 2015

Five things for pharma marketers to know: Thursday, October 29, 2015

Pfizer in merger talks with Allergan; comparative effectiveness council says PCSK9s aren't worth the money; pharmacy tied to Valeant used "back-door" sales tactics

Five things for pharma marketers to know: Wednesday, October 28, 2015

Five things for pharma marketers to know: Wednesday, October 28, 2015

Walgreens buys Rite Aid in $9.4 billion deal; Arena fires a third of its workforce and discontinues Belviq clinical trials; FDA approves Amgen melanoma immunotherapy

Five things for pharma marketers to know: Wednesday, October 14, 2015

Five things for pharma marketers to know: Wednesday, October 14, 2015

J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies

Five things for pharma marketers to know: Friday, September 25, 2015

Five things for pharma marketers to know: Friday, September 25, 2015

Teva acquires sensor-based inhaler; EU conditionally approves Amgen's cancer drug, Blincyto; Novartis CEO says targeted therapies may reduce unnecessary US healthcare spending

New Turing CCO steps down amid drug price controversy

New Turing CCO steps down amid drug price controversy

Craig Rothenberg joined Turing as its first comms chief less than two months ago.